Protocol Ledger

NCT05348785 · Phase II · COMPLETED

A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80

Interventional Phase II clinical trial protocol NCT05348785 sponsored by Biogen in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-04-19 Enrollment: 650 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05348785
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)650 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05348785
Protocol FieldVerified Registry Value
NCT IdentifierNCT05348785
Consolidated Lead SponsorBiogen
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment650 participants (ACTUAL)
Registered Start Date2022-04-19
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Biogen across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI